PHARMACOKINETICS AND EX-VIVO SUSCEPTIBILITY OF CEFPODOXIME PROXETIL IN PATIENTS RECEIVING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS

Pharmacokinetics of cefpodoxime, an extended-spectrum cephalosporin, w ere determined for eight noninfected patients on continuous ambulatory peritoneal dialysis (CAPD) and eight healthy volunteers. Subjects wer e matched for sex, age (+/-6 years), and body weight (+/-10 kg, except for one pair) and received a single 200-mg (cefpodoxime equivalents) oral dose of the prodrug cefpodoxime proxetil in an open-label, paired -design fashion. Dialysate (CAPD group only), plasma, and urine sample s were collected and assayed for cefpodoxime by a microbiologic method . In addition, mean bactericidal titers of the effluent dialysate agai nst selected bacterial strains often associated with CAPD-related peri tonitis were determined at 6 and 24 h after the dose. There was a sign ificant difference (P<0.05) in all pharmacokinetic parameters between healthy and CAPD subjects, except for lag time to absorption. The mean peak plasma cefpodoxime concentration of 1.88 +/- 0.6 mu g/ml occurre d at 2.44 +/- 0.5 h for healthy volunteers, while the peak concentrati on of 3.25 +/- 1.4 mu g/ml occurred at 12.0 +/- 4.2 h for patients on CAPD. The average elimination half-life in CAPD patients was approxima tely 12 times greater than that seen in healthy volunteers. Peritoneal dialysis had a minimal effect on cefpodoxime clearance. In healthy vo lunteers, 24.2% +/- 13% of the dose was recovered from the urine, in c ontrast to only 5.59% +/- 6.9% for CAPD patients. The mean bactericida l titers for all CAPD patients, at 6 and 24 h, were mostly less than 1 :2 and did not exceed 1:4 for any of the isolates. Because of the decr eased renal clearance and negligible dialysate clearance of cefpodoxim e, and delayed drug absorption, the dosage interval for cefpodoxime pr oxetil may need to be extended in CAPD patients.